Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Bluejay Therapeutics LLC is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The portfolio's active prosecution is concentrated under 1 distinct examiner and 1 distinct art unit. CHEN, PO-CHIH is the busiest examiner, holding the 1 pending action currently on record. This centralized structure means the outcome of the current pending action rests entirely with one examiner and one administrative unit within the USPTO.
A practitioner handling this case must focus on the specific examination patterns of CHEN, PO-CHIH, as there are no other pending actions to provide alternative paths to allowance. The busiest examiner's workload of 1 pending action matches the total volume of the portfolio's current activity. This lack of diversification across examiners or art units means that any challenges encountered during the prosecution of this single action cannot be mitigated by progress in other cases. The strategy must be precisely aligned with the Biotechnology & Pharmaceuticals standards of the 1 distinct art unit involved. Success in this matter is the sole focus of the current prosecution effort.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHEN, PO-CHIH | 1 | 74.3% | +14.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18747436 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | CHEN, PO-CHIH | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18747436 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | CHEN, PO-CHIH | 1621 | §112 | Non-Final OA | — | Pending | Jun 18, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBluejay Therapeutics LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Po-Chih Chen has the most, with 1 of Bluejay Therapeutics LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
